tuberculosis Current Affairs - 2019
Category Wise PDF Compilations available at This Link
The Member Countries of World Health Organization-Regional Office for South-East Asia (WHO-SEARO), participating in Delhi End Tuberculosis (TB) Summit have adopted ‘Delhi End TB Summit Statement of Action’.
The summit was co-hosted by Ministry of Health and Family Welfare, WHO-SEARO and Stop TB Partnership in New Delhi. It was inaugurated by Prime Minister Narendra Modi and also launched TB Free India Campaign.
Delhi End TB Summit Statement of Action
It identifies roles, responsibilities and directions of member countries of WHO SEARO region to make their countries free from this disease. It commends increased attention, investments and efforts directed at tackling region’s major burden of tuberculosis (TB).
It also expresses concern that most low-burden countries are yet to establish last mile programmes for early ending of TB. It reiterates firm intent to implement response in each of our nations that is demonstrably adequate for ending TB by 2030 and meeting milestones for 2020 by collectively reaching out to missing 2 million BT cases and 150000 multidrug-resistant cases.
- LEAD implementation of national TB responses in countries by empowered national initiative that monitors progress in reaching End TB targets to the highest levels of government in Member States.
- INCREASE budgetary and human resource allocations by governments as well as by their global, domestic and other partners so as to ensure that national TB plans are fully funded.
- ENABLE best possible care to each and every person, including migrants, aged and other high-risk populations, living with any form of TB including drug-resistant TB/ HIV co-infections.
- SUPPLEMENT medical care for TB with social and financial protection in holistic manner.
Tags: Delhi End TB Summit Statement of Action • Delhi End-TB Summit • Diseases • LEAD-INCREASE-ENABLE-SUPPLEMENT Priorities • Ministry of Health and Family Welfare • National • Public Health • tuberculosis • WHO-SEARO
The Indian Council of Medical Research (ICMR) was awarded 2017 Kochon Prize for building tradition of excellence in Tuberculosis (TB) research and development. It had emerged winner from among 18 nominations.
It was awarded for establishing India TB Research Consortium to accelerate R&D efforts in the country. The consortium is working with public and private institutes to guide country’s research efforts towards development of point-of-care diagnostics, shorter treatment regimens and effective vaccine for TB.
Indian Council of Medical Research (ICMR)
The ICMR is India’s apex scientific body for the formulation, coordination and promotion of biomedical research. It was established in 1911 as Indian Research Fund Association (IRFA) making it one of the oldest and largest medical research bodies in the world. The ICMR functions under the Department of Health Research, Union Ministry of Health and Family Welfare. It is headquartered in New Delhi.
ICMR’s Governing Body is presided over by Union Health Minister. It is assisted in scientific and technical matters by Scientific Advisory Board comprising eminent experts in different biomedical disciplines. Its research priorities coincide with National health priorities such as control and management of communicable diseases, fertility control, maternal and child health, control of nutritional disorders, research on major non-communicable diseases like cancer, cardiovascular diseases, blindness, diabetes and mental health research and drug research (including traditional remedies) and developing alternative strategies for health care delivery,
The Kochon Prize is awarded annually by Stop TB Partnership to individuals and organizations that have made significant contribution to combating the disease. The prize is endowed by Kochon Foundation, a non-profit foundation registered in South Korea. It consists of prize of US $65,000 award.
The prize was established in 2006 in honour of late Chairman Chong-Kun Lee (left), founder of Chong Kun Dang Pharmaceutical Corporation and Kochon Foundation. He was committed throughout his career to improve access to low-cost lifesaving antibiotics and anti-TB drugs.